[go: up one dir, main page]

WO2011093819A3 - New pharmaceutical combination comprising tiotropium - Google Patents

New pharmaceutical combination comprising tiotropium Download PDF

Info

Publication number
WO2011093819A3
WO2011093819A3 PCT/TR2011/000021 TR2011000021W WO2011093819A3 WO 2011093819 A3 WO2011093819 A3 WO 2011093819A3 TR 2011000021 W TR2011000021 W TR 2011000021W WO 2011093819 A3 WO2011093819 A3 WO 2011093819A3
Authority
WO
WIPO (PCT)
Prior art keywords
tiotropium
pharmaceutical combination
new pharmaceutical
ciclesonide
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/TR2011/000021
Other languages
French (fr)
Other versions
WO2011093819A2 (en
Inventor
Mahmut Bilgic
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of WO2011093819A2 publication Critical patent/WO2011093819A2/en
Publication of WO2011093819A3 publication Critical patent/WO2011093819A3/en
Priority to US13/531,972 priority Critical patent/US8834931B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

A pharmaceutical composition comprising tiotropium bromide, formoterol fumarate and ciclesonide, and its use in the symptomatic and/or prophylactic treatment of respiratory diseases especially asthma, allergic rhinitis, chronic obstructive pulmonary disease (COPD).
PCT/TR2011/000021 2009-12-25 2011-01-28 New combination comprising tiotropium Ceased WO2011093819A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US13/531,972 US8834931B2 (en) 2009-12-25 2012-06-25 Dry powder formulation containing tiotropium for inhalation

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
TR2010/00623A TR201000623A2 (en) 2010-01-28 2010-01-28 New tiotropium combination.
TR2010/00623 2010-01-28

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000022 Continuation-In-Part WO2011093820A2 (en) 2009-12-25 2011-01-28 A pharmaceutical combination comprising tiotropium

Related Child Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000019 Continuation-In-Part WO2011093817A1 (en) 2009-12-25 2011-01-28 Pharmaceutical compositions comprising tiotropium, formoterol and budesonide

Publications (2)

Publication Number Publication Date
WO2011093819A2 WO2011093819A2 (en) 2011-08-04
WO2011093819A3 true WO2011093819A3 (en) 2012-02-23

Family

ID=43898675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2011/000021 Ceased WO2011093819A2 (en) 2009-12-25 2011-01-28 New combination comprising tiotropium

Country Status (2)

Country Link
TR (1) TR201000623A2 (en)
WO (1) WO2011093819A2 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013109219A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising tiotropium and carmoterol
WO2013109212A1 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Dry powder formulations comprising ciclesonide
WO2013109216A2 (en) * 2012-01-16 2013-07-25 Mahmut Bilgic Preparation of dry powder formulations comprising tiotropium
WO2014007773A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Compositions comprising muscarinic receptor antagonist and sorbitol
WO2014007768A1 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Dry powder inhaler compositions comprising long acting muscorinic antagonists
US20150174064A1 (en) * 2012-07-05 2015-06-25 Arven IIac Sanayi Ve Ticaret A.S. Compositions comprising muscarinic receptor antagonist and glucose anhydrous
US10111957B2 (en) 2012-07-05 2018-10-30 Arven Ilac Snayi ve Ticaret A.S. Inhalation compositions comprising glucose anhydrous
WO2014007771A2 (en) * 2012-07-05 2014-01-09 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Inhalation compositions comprising muscarinic receptor antagonist
TR201712424A2 (en) * 2017-08-21 2019-03-21 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi DRY POWDER INHALATION COMPOSITIONS

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019985A1 (en) * 2002-08-29 2004-03-11 Cipla Ltd Pharmaceutical products and compositions comprising specific anticholinergic agents, beta-2 agonists and corticosteroids
US20090188497A1 (en) * 2003-12-03 2009-07-30 Boehringer Ingelheim International Gmbh Medical product containing tiotropium
WO2008102128A2 (en) * 2007-02-19 2008-08-28 Cipla Limited Pharmaceutical combinations of at least two bronchodilators or of a bronchodilator with a corticosteroid

Also Published As

Publication number Publication date
TR201000623A2 (en) 2011-08-22
WO2011093819A2 (en) 2011-08-04

Similar Documents

Publication Publication Date Title
WO2011093819A3 (en) New pharmaceutical combination comprising tiotropium
WO2011093820A3 (en) A pharmaceutical combination comprising tiotropium
EP2749280A3 (en) Combination of glycopyrronium and formoterol
TR201000680A2 (en) Pharmaceutical compositions containing tiotropium, formoterol and budesonide
WO2006117300A3 (en) Crystalline forms of tiotropium bromide
EP2085396A3 (en) Novel crystalline forms of tiotropium bromide
HK1206670A1 (en) Method and apparatus
WO2010094731A3 (en) Pharmaceutical composition for inhalation
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
IL213959A (en) Inhalable corticosteroid, as a nebulized aerosol in the gas phase, for use in the treatment of a patient having severe and uncontrolled asthma
WO2012016889A3 (en) Dry powder formulation comprising a phosphodiesterase inhibitor
NO20063879L (en) The combination of anticholinergics and glucocorticoids for long-term treatment of asthma and COPD
WO2014064410A8 (en) Pharmaceutical composition
IL199022A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
EA201201397A1 (en) INHALER CONTAINING DISTRIBUTED GLISTER PACKING
EP2682097A3 (en) Dry Powder Inhalers Comprising A Carrier Other Than Lactose
MY146628A (en) Novel crystalline anhydride with anticholinergic effect
WO2011152804A3 (en) Process for dry powder formulations
EA201201392A1 (en) PUSH-BUTTON DEVICE
EP2120935A4 (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma
EA201201389A1 (en) INHALER, CREATING TURBULENCE
IL189182A0 (en) A combination of compounds, which can be used in the treatment of respiratory diseases, especially chronic obstructive pulmonary disease (copd) and asthma
UA115989C2 (en) Dry powder inhaler compositions comprising long acting muscorinic antagonists
MX2016001539A (en) Inhalable particles comprising tiotropium and indacaterol.
EP2125728A4 (en) Novel combination of compounds to be used in the treatment of airway diseases, especially chronic obstructive pulmonary disease (copd) and asthma

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11706046

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11706046

Country of ref document: EP

Kind code of ref document: A2